Philadelphia, Pennsylvania--(Newsfile Corp. - February 24, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Mereo BioPharma Group plc (NASDAQ: MREO) ("Mereo" or the "Company") on behalf of investors who purchased Mereo American Depositary Shares (ADS) during the period from June 5, 2023 through December 26, 2025 (the "Class Period").Investor Deadline: Investors who purchased Mereo securities during the Class Period may, no later than Apr ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Mereo BioPharma Group plc due to alleged violations of federal securities laws related to misleading statements about clinical trial results [2][4]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Mereo BioPharma to contact them to discuss their legal options [1]. - There is a deadline of April 6, 2026, for investors to seek the role of lead plaintiff in a federal securities class action against Mereo [2][7]. Group 2: Clinical Trial Results - Mereo announced that two Phase 3 studies of setrusumab failed to meet their primary endpoints of reducing annualized clinical fracture rates compared to placebo and bisphosphonates [5]. - Despite the failure to meet primary endpoints, the trials showed statistically significant improvements in bone mineral density on secondary endpoints, and no new safety concerns were identified [5]. Group 3: Market Reaction - Following the announcement of the failed trials, Mereo's stock price fell by $2.02 per share, or 87.64%, closing at $0.28 per share on December 29, 2025 [6].

NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- From a closing price of $2.31 on December 26, 2025, Mereo BioPharma Group plc (NASDAQ: MREO) shares plummeted to $0.29 on December 29, 2025—a decline of more than 87.7%—as corrective disclosures allegedly revealed that neither the ORBIT nor COSMIC Phase 3 studies achieved statistical significance. Investors have until April 6, 2026 to seek lead plaintiff status. See if you can recover losses or contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com | (212) 363-75 ...

New York, New York--(Newsfile Corp. - February 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Shares ("ADS") of Mereo BioPharma Group plc (NASDAQ: MREO) between June 5, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline.SO WHAT: If you purchased Mereo ADSs during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contin ...

Core Viewpoint - Rosen Law Firm is reminding purchasers of American Depositary Shares (ADS) of Mereo BioPharma Group plc about the upcoming lead plaintiff deadline for a class action lawsuit related to misleading statements made by the company regarding its clinical studies [1]. Group 1: Class Action Details - The class action pertains to Mereo ADSs purchased between June 5, 2023, and December 26, 2025, with a lead plaintiff deadline set for April 6, 2026 [1]. - Investors who purchased Mereo ADSs during the specified period may be eligible for compensation without incurring out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Legal Process - Interested parties can join the class action by visiting the provided link or contacting the law firm directly for more information [3][7]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by the April 6, 2026 deadline [3]. Group 3: Case Background - The lawsuit claims that Mereo BioPharma provided investors with optimistic statements regarding the Phase 3 Orbit and COSMIC studies for setrusumab in treating Osteogenesis Imperfecta (OI), suggesting confidence in the drug's efficacy [5]. - However, the defendants allegedly concealed material adverse facts, as neither study achieved its primary endpoints, leading to artificially inflated prices for Mereo's ADSs [6].

NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Shares (“ADS”) of Mereo BioPharma Group plc (NASDAQ: MREO) between June 5, 2023 and December 26, 2025, inclusive (the “Class Period”), of the important April 6, 2026 lead plaintiff deadline. SO WHAT: If you purchased Mereo ADSs during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arra ...

New York, New York--(Newsfile Corp. - February 19, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Shares ("ADS") of Mereo BioPharma Group plc (NASDAQ: MREO) between June 5, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline.SO WHAT: If you purchased Mereo ADSs during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contin ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Mereo BioPharma To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Mereo between June 5, 2023 and December 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Fa ...

Core Viewpoint - Mereo BioPharma Group plc is facing a class action lawsuit due to allegations of misleading statements regarding the Phase 3 ORBIT and COSMIC programs, which failed to meet their primary endpoints, leading to a significant drop in stock price [3]. Group 1: Allegations and Impact - The class period for the lawsuit is from June 5, 2023, to December 26, 2025 [3]. - Defendants allegedly provided overly positive statements while concealing adverse facts about the Phase 3 ORBIT and COSMIC programs, which did not achieve statistical significance in reducing annualized clinical fracture rates [3]. - Following the announcement on December 29, 2025, that neither study met its primary endpoint, Mereo's ADS price plummeted from $2.31 to $0.29, a decline of over 87.7% [3]. Group 2: Next Steps for Shareholders - Shareholders are encouraged to register for the class action by April 6, 2026, to participate in potential recovery [4]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the case lifecycle [4]. Group 3: Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements [5].

Core Viewpoint - A class action has been filed against Mereo BioPharma Group plc for allegedly misleading investors regarding the Phase 3 ORBIT and COSMIC studies for setrusumab, which did not meet their primary endpoints, leading to significant financial losses for shareholders [1][2][3]. Group 1: Allegations and Misleading Information - The complaint alleges that Mereo BioPharma provided investors with overly optimistic statements about the expected results of the Phase 3 ORBIT and COSMIC studies for setrusumab, claiming it would reduce annualized fracture rates [2]. - It is claimed that while Mereo expressed confidence in the studies, they concealed material adverse facts about the true state of the ORBIT and COSMIC programs, which ultimately failed to meet their primary endpoints [2]. Group 2: Impact on Stock Price - Following the announcement on December 29, 2025, that neither the ORBIT nor COSMIC studies met their primary endpoint, Mereo's American Depository Shares (ADS) plummeted from $2.31 per share to $0.29 per share, marking a decline of over 87.7% [3]. Group 3: Class Action Participation - Shareholders may be eligible to participate in the class action against Mereo BioPharma, with a deadline to submit papers to serve as lead plaintiff by April 6, 2026 [4]. - Shareholders do not need to participate in the case to be eligible for recovery and can remain absent class members if they choose [4].